Ophthalmology News

Valeant Pharmaceuticals International announced today in a press release new fulfillment agreements in which Valeant will reduce prices of its branded prescription-based dermatological and ophthalmological products by 10%.

The NIH has announced that it will spend $2.2 million to fund the development of robots that will help the elderly, the young and those with vision impairments, according to a press release issued by the research center.

SAN FRANCISCO – Patients with uveitis related to juvenile idiopathic arthritis may benefit from therapy with Humira and background methotrexate, according to a recently presented study.

Allergan today announced that it has been approached by Pfizer and is in preliminary discussions regarding a potential business combination transaction, according to a press release.

WASHINGTON — The growing popularity of nonpowder firearms, including paintball guns, airsoft guns, BB guns and pellet guns, represent a significant risk of ocular injury among children with the potential for permanent disability, according to data presented at the 2015 AAP National Conference and Exhibition.

The Subcommittee on Primary Health and Retirement Security met on Thursday, September 17 for a hearing on the implementation of biosimilar agents with Janet Woodcock, MD, director of the Center for Drug Evaluation and Research at the FDA, and among other questions about interchangeability and safety, some senators questioned the lack of action in the issuance of guidance documents.

Nearly all contact lens wearers who participated in an online survey took part in behaviors that may increase the risk of eye infection, the Centers for Disease Control and Prevention reported today.

Xoma today announced gevokizumab failed to meet its primary endpoints in a phase 3 trial in patients with uveitis caused by Behçet’s disease, according to a company press release.

The FDA has announced that there are potential vision loss risks because of pigment changes in the retina and possible skin discoloration for patients treated with the anti-seizure drug Potiga, according to reviews of additional safety data.

BOSTON ─  In a packed meeting room, Lynn K. Gordon, MD, PhD, presented her update on what she calls “office ophthalmology” here at the ACP Internal Medicine meeting.